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Core tip: Higly active antiretroviral therapy has de-
creased the mortality and morbidity of human immuno-
deficiency virus (HIV)-infected adults and children, too. 
Many of the antiviral drug used can cause side effects 
and in particular renal toxicity. A monitoring of renal 
function is useful for the management of HIV-infected 
patients.
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INTRODUCTION
In human immunodeficiency virus (HIV)-infected peo-
ple kidney disease has recently emerged as an important 
cause of  morbidity and mortality. HIV, can cause severe 
kidney disease directly, including acute kidney injuries, 
thrombotic microangiopathies, HIV-associated nephropa-
thy (HIV-AN), and HIV immune complex kidney disease 
(HIV-ICK). Likewise, many co-morbidity, such as tuber-
culosis, opportunistic and bacterial infections and sexu-
ally transmitted infections can cause a variety of  kidney 
disorders that may affect the outcome of  HIV infection. 
Rao et al[1] divided the HIV-1-associated renal parenchy-
mal diseases in four groups: (1) acute tubular dysfunc-
tion with electrolytes abnormalities and/or renal failure 
caused by infections and nephrotoxic drugs; (2) HIV 
glomerulophaties related to immunological abnormalities; 
(3) HIV-associated thrombotic microangiopathies; and (4) 
HIV-AN.
Before highly active antiretroviral treatment (HAART), 
an association of  renal impairment with faster progres-
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Abstract
In human immunodeficiency virus (HIV)-infected people 
kidney disease is as an important cause of morbidity 
and mortality. Clinical features of kidney damage in 
HIV-infected patients range from asymptomatic micro-
albuminuria to nephrotic syndrome. The lack of specific 
clinical features despite the presence of heavy pro-
teinuria may mask the renal involvement. Indeed, it is 
important in HIV patients to monitor renal function to 
early discover a possible kidney injury. After the intro-
duction of antiretroviral therapy, mortality and morbidi-
ty associated to HIV-infection have shown a substantial 
reduction, although a variety of side effects for long-
term use of highly active antiretroviral therapy, includ-
ing renal toxicity, has emerged. Among more than 20 
currently available antiretroviral agents, many of them 
can occasionally cause reversible or irreversible nephro-
toxicity. At now, three antiretroviral agents, i.e. , indina-
vir, atazanavir and tenofovir disoproxil fumarate have a 
well established association with direct nephrotoxicity. 
This review focuses on major causes of proteinuria and 
other pathological findings related to kidney disease in 
HIV-infected children and adolescents.
© 2013 Baishideng. All rights reserved.
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sion to acquired immunodeficiency syndrome and death 
in HIV-infected people was demonstrated[2]. Hence, in 
the United States approximately 40% of  all HIV-infected 
children presented renal complications. Among them, 
10%-15% developed a renal disease named HIV-AN[3,4]. 
HIV-AN has been described as a clinical and renal histo-
logical syndrome characterized by heavy proteinuria and 
rapid progression to end-stage kidney disease[5,6]. Histo-
pathological findings include collapsing glomerulopathy, 
global or focal glomerulosclerosis, microcystic transfor-
mation of  renal tubules, interstitial inflammation and 
hyperplasia of  podocytes[7]. A genetic predisposition was 
supposed on the demonstration of  the unique suscepti-
bility of  African-Americans to the development of  this 
disease, although the responsible genes have not yet been 
identified[8,9]. The finding of  HIV-AN in children pro-
vided strong evidence that HIV-1 per se was capable of  
inducing renal disease independently of  other confound-
ing variables that are present in HIV-infected adults (such 
as heroin abuse)[10].
Clinical features of  kidney damage in HIV-infected 
patients range from asymptomatic microalbuminuria to 
full-blown nephrotic syndrome[11]. Children with HIV-
related kidney disease may also develop acute kidney 
injury, thrombotic microangiopathies (including atypical 
forms of  haemolytic uraemic syndrome) and some may 
progress to chronic kidney disease (CKD)[4]. The most 
common presentation is nephrotic syndrome, followed 
by anasarca and moderate range proteinuria. Edema and 
hypertension, in accordance with reports from adults, are 
rare in children with kidney disease[5]. The lack of  clinical 
features despite the presence of  heavy proteinuria may 
mask the renal involvement. Indeed, it is important in 
HIV-infected patients to monitor renal function to early 
discover a possible kidney injury.
After the introduction of  antiretroviral therapy, mor-
tality and morbidity associated to HIV-infection have 
shown a substantial reduction, although a variety of  side 
effects for long-term use of  HAART, including renal tox-
icity, has emerged[12,13].
Among more than 20 currently available antiretroviral 
agents, many of  them can occasionally cause reversible 
or irreversible nephrotoxicity. Many of  the nucleoside 
reverse transcriptase inhibitors, particularly older agents 
like didanosine, have been implicated as a cause of  type B 
lactic acidosis, but this acid-base imbalance is not, strictly 
speaking, renal toxicity. Only three antiretroviral agents, 
i.e., indinavir, atazanavir (ATV) and tenofovir disoproxil 
fumarate (TDF) have a well established association with 
direct nephrotoxicity. 
Indinavir is an antiretroviral agent belonging to the 
protease inhibitor class. It was among the first agents used 
as a part of  potent combination HAART and the most 
commonly protease inhibitor used in 1996, but nowadays, 
because of  its inconvenient dosing, meal restrictions and 
nephrolithiasis, it is only rarely prescribed. Indinavir no-
toriously causes renal and urologic toxicity mediated by 
tubular crystallization[14,15]. Guidelines recommend that 
patients receiving indinavir drink at least 1.5 L of  water a 
day and that periodic urinalysis and monitoring of  serum 
creatinine concentration be performed.
ATV is a newer antiretroviral agent belonging to the 
protease inhibitor class characterized by an excellent toler-
ability and a potent efficacy in controlling HIV infection. It 
is poorly soluble in urine and easily precipitating at alkaline 
pH. In contrast to indinavir, clinically significant crystal-
luria and associated interstitial nephritis were not observed 
in patients treated with ATV, whereas several reports de-
scribed ATV nephrolithiasis[16,17]. Two recent publications 
estimated the relation between CKD and antiretroviral 
drug use in HIV-positive patients. Mocroft et al[18] analysed 
a cohort of  225 subjects showing that 3.3% persons pro-
gressed to CKD during 21 482 persons-year follow-up, 
thus resulting in CKD incidence of  1.05 per 100 person-
year follow up. After adjusting for traditional risk factor 
associated with CKD and other confounding variables, 
increasing cumulative exposure to ATV (IRR 1.21, 95%CI: 
1.09-1.34) and lopinavir/r were associated with a signifi-
cant increased risk rate of  CKD. Dauchy et al[19] in the 
Aquitaine cohort demonstrated that the use of  ATV is 
associated with an increased risk of  proximal renal tubular 
dysfunction (1.28 per year of  exposure). Lastly Rockwood 
examinated the development of  renal stones in a cohort of  
HIV-infected individuals attending the Chelsea and West-
minster Hospital Foundation Trust exposed to different 
antiretrovirals. The rate of  development of  renal stones 
in the ATV/r group (n = 1206) compared with efavirenz-
lopinavir/r-darunavir/r combined group (n = 4449) was 7.3 
per 1000 patients years of  antiretroviral therapy exposure 
(95%CI: 4.7-10.8). Thus ATV/r renal stones should be 
considered as a potential comorbidity[20].
TDF is a nucleotide reverse transcriptase inhibitor. 
It is currently widely used due to its excellent properties, 
combining good potency, tolerability and convenience, 
either as a single agent or co-formulated with emtric-
itabine or with emtricitabine plus efavirenz[21]. TDF 
showed a relatively good safety profile in registrational 
clinical trials, but subsequently a number of  reports have 
alerted about cases of  tubular damage and occasionally 
of  renal insufficiency in patients treated with TDF[22-24]. 
The pathogenesis of  renal damage caused by TDF re-
mains unclear[25,26]. Reviews of  reported cases of  TDF-
associated nephrotoxicity suggest that it mostly manifests 
as proximal tubular injury with associated reduction in 
glomerular filtration rate (GFR). Patients often develop 
glycosuria, tubular proteinuria, lowered serum phosphate 
and increased serum creatinine. Some patients may de-
velop frank Fanconi’s syndrome or reduced bone mineral 
density. Thus, it is important to early and accurately di-
agnose TDF-associated nephrotoxicity[27]. If  many data 
are available for adult patients, the renal safety of  TDF 
in HIV-infected children and adolescents has not been 
well documented. Although sporadic cases of  renal toxic-
ity have been reported in HIV-infected children treated 
with TDF, a report describes renal safety outcome after 
96 wk of  use of  tenofovir in HIV-infected children and 
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adolescents. The findings suggest that 96-wk use of  TDF 
is not associated with any impairment of  glomerular and 
tubular renal function in children with normal renal func-
tion at baseline[28]. According to another 60 mo follow-
up study in HIV-infected children, adolescents and young 
adults treated with TDF, this antiretroviral drug has an 
excellent renal safety profile[29]. It stands to reason that 
TDF renal safety needs to be further evaluated in chil-
dren, in particular in those who may be at higher risk as a 
result of  pre-existing renal disease and concomitant use 
of  nephrotoxic drugs. Moreover, given the need for long-
term exposure to antiretroviral therapy in HIV pediatric 
patients, the renal safety of  TDF could be better defined 
by longer observational studies.
Early detection and treatment of  potentially serious 
kidney problems are especially critical for people living 
with HIV, since many of  these cases are reversible or 
their evolution can be slowed if  recognized in time[30,31]. 
NEPHROPATHY AND DIAGNOSTIC TESTS
With the exception of  the rather dramatic clinical pre-
sentations seen with a severe or complete loss of  kidney 
function, many kidney disorders are asymptomatic or the 
symptoms are non-specific, such as fatigue, loss of  ap-
petite, nausea, headache, etc. For this reason, many kidney 
disorders can only be recognized with laboratory tests. 
The biomarkers currently used to detect kidney injury 
or monitor kidney function have limited sensitivity or 
dubious accuracy and have not been well studied in HIV-
infected people, according to a recent review by Post 
et al[32]. Other markers, which may provide a better and 
earlier indication of  specific forms of  kidney damage, 
including tenofovir-related proximal tubule damage, are 
being investigated.
HIV-infected people can present with the classic clini-
cal features of  the nephrotic syndrome, such as heavy 
proteinuria, edema and hypoalbuminemia. The renal 
disease may also be clinically manifested by persistent 
and isolated proteinuria[4]. CKD is determined by the 
presence of  kidney damage, indicated by albuminuria or 
proteinuria, or GFR below 60 mL/min per 1.73 m2 for ≥ 
3 mo[33]. Kidney disease and GFR are directly correlated, 
and the latter typically decreases before the onset of  
symptoms of  kidney failure[34]. Several equations to cal-
culate GFR exist. The Cockcroft-Gault equation, which 
uses the 24-h urine creatinine clearance as indirect refer-
ence method, was the first and most attractive formula 
validated in adults. However, the need of  body weight 
in the equation has greatly limited its practicability for 
widely use in renal medicine. Subsequently, the modifica-
tion of  diet in renal disease (MDRD) equation adjusted 
for four variables (age, gender, serum creatinine and 
ethnicity) was validated by Levey et al[35]. In addition, the 
same author recommended that the constant factor used 
in the original equation should be re-expressed using a 
new constant, if  creatinine measurement is standardized 
against Isotope Dilution-Mass Spectrometry (reference 
method). Extensive evaluation of  the MDRD study 
equation shows good performance in population with 
lower levels of  eGFR but variable performance in those 
with higher levels[36]. To overcome the above mentioned 
pitfalls, the MDRD equation was revisited again by its 
original author[37] and modified into a new equation: the 
CKD epidemiology collaboration (CKD-EPI) equation. 
Therefore, it was suggested to replace the MDRD equa-
tion with CKD-EPI in clinical use in adults. 
In children over 12 years of  age, the Cockcroft-Gault 
equation is the most frequently used. For children under 
12 years of  age, Schwartz formula enables to calculate 
GFR using length in place of  weight[38]. Although these 
equations are used in clinical practice as well as in several 
studies conducted in HIV-infected children and adults to 
evaluate GFR, none of  them have been really validated in 
these cohorts of  patients[27].
The diagnosis of  kidney injury may include albumin-
uria and proteinuria testing. Proteinuria is believed to be 
the earliest and most consistent clinical finding for the 
diagnosis of  HIV-AN[39,40]. Han et al[11] have reported the 
presence of  microalbuminuria as an early marker of  HIV-
AN in adults. Urine albumin-to creatinine ratios (ACR) or 
protein-to-creatinine ratios (PCR) are reproducible mea-
surements of  proteinuria. Micro and macroalbuminuria 
are defined by ACRs > 30 mg/g and > 300 mg/g, respec-
tively, while significant proteinuria is defined by a PCR > 
200 mg/g. While albuminuria is more specific to glomeru-
lar injury (such as is seen in HIV-AN), proteinuria, that 
predominately includes albumin with other proteins, can 
be an indicator of  either a glomerular or tubular defect. 
The most widely available tests that screen for proteinuria 
and albuminuria are urine dipstick test. However, a recent 
study has demonstrated that the sensitivity of  dipstick test, 
may be affected by urinary concentration[41]. So dipstick 
tests may miss about one out of  five people with kidney 
disease, and positive dipstick test results for proteinuria 
may have to be confirmed by other lab tests. Dipstick test 
has been efficiently used by Ray et al[3] in association with 
other tests to diagnose HIV-AN through the following 
criteria: (1) persistent proteinuria, defined as an albus-
tix reading above 1+ or a urinary protein-to-creatinine 
clearance ratio more than 0.1 for more than 2 mo in the 
absence of  acute infection episodes; (2) abnormal micro-
scopic examination of  the urinary sediment under similar 
conditions, which in some cases included the presence 
of  urine microcysts; (3) presence of  enlarged echogenic 
kidneys detected by renal ultrasonography in at least two 
different studies performed 2 mo apart; and (4) black race 
and clinical history consistent with the typical diagnosis 
of  HIV-AN (i.e., nephrotic-range proteinuria without sig-
nificant oedema and/or severe hypertension). Nephrotic 
range proteinuria has been defined by Ramsuran et al[42] as 
a PCR of  ≥ 2.0 and by Chaparro et al[43] as a PCR of  > 1.0. 
Proteinuria in children is an important prognostic fac-
tor for HIV-associated renal disease, and it needs to be 
assessed in follow-up to diagnose concurrent potentially 
progressive renal disease. As much as one third of  the 
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population may present proteinuria, but no more than 
10% generally have a real nephropathy, defined as ne-
phrotic-range proteinuria, which may benefit of  HAART 
or angiotensin blockade therapy. Surveillance of  quantita-
tive proteinuria in conjunction with imaging and chemi-
cal indicators of  renal dysfunction is very much war-
ranted. It seems reasonable to propose nephrotic range 
proteinuria as a major criterion for defining the clinical 
nephropathy in children and would be a clear indication 
for renal biopsy and initiation of  HAART in naive pa-
tients[44,45]. Biopsy diagnosis can reveal the typical histo-
logical features of  minimal change nephrotic syndrome, 
mesangioproliferative glomerular lesions, and “lupus-like” 
renal lesions[3,10,39,46,47]. Other patients show renal changes 
consistent with the diagnosis of  HIV-AN or HIV-ICK[47]. 
Thus, performing a renal biopsy is the only way to estab-
lish a definitive diagnosis.
People with kidney disease localized in the renal tu-
bule such as Fanconi’s syndrome may have mild protein-
uria composed of  other proteins but rarely of  albumin. 
The presence of  renal tubular disorders in HIV-infected 
African American and Venezuelan patients has been rec-
ognized through hypercalciuria with a potential for neph-
rocalcinosis, and less frequently with crystalluria, hyper-
chloremia, and metabolic acidosis[3,10,39]. Tubular disorders 
may induce sodium, potassium, and phosphate wasting 
states. Elevated fractional urinary excretion of  phosphate 
is perhaps an earlier marker of  proximal tubular dysfunc-
tion and might be useful in monitoring for TDF toxicity.
Besides proteinuria, there are a number of  other bio-
markers that could potentially be more specific for tubu-
lar inflammation or damage and that may serve as earlier 
and better indications of  which patients are likely to 
experience tenofovir-associated toxicity. Post et al[32] note 
that since the proximal tubule is supposed to reabsorb 
substances such as low molecular weight proteins, in-
creased excretion of  these in the urine could indicate tu-
bular dysfunction[48,49]. Tests for these markers are not yet 
affordable or widely available and research into the use of  
these substances as biomarkers for renal tubule disorders 
is still in its infancy. Therefore it would be worth under-
line that a urine high PCR in conjunction with a normal 
or low urine albumine-to-creatinine ratio may identify 
patients with renal tubular disorders[50]. Thus, the assess-
ment of  these markers may be very useful to discover the 
proximal tubular dysfunction induced by TDF exposure.
In the meantime, studies using these markers as evi-
dence of  kidney damage should be interpreted with cau-
tion.
Table 1 is provided to summarize the different fea-
tures of  proteinuria in different HIV-associated kidney 
diseases in children.
CONCLUSION
A prompt diagnosis of  nephrotoxicity due to antiretrovi-
ral therapy in HIV-infected patients allows to take rapid 
steps to mitigate damage to the kidney. It is also impor-
tant to distinguish it from other causes of  HIV-associated 
renal diseases. The collaboration with a nephrologists, the 
close monitoring of  renal function and the biopsy in case 
of  progressive renal disease allow to establish an accurate 
diagnosis. 
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